{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:54:58Z","timestamp":1781513698974,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Medical Scientific Research Project of the Health and Wellness Committee of Hongkou District, Shanghai","award":["HW2503-07"],"award-info":[{"award-number":["HW2503-07"]}]},{"name":"the Scientific Research Project of the Discipline Boosting Program of the Shanghai Fourth People's Hospital","award":["SY-XKZT-2025-1014"],"award-info":[{"award-number":["SY-XKZT-2025-1014"]}]},{"name":"the Bethune Charitable Foundation","award":["Z04JKM2023E040 and Z04J2023E095"],"award-info":[{"award-number":["Z04JKM2023E040 and Z04J2023E095"]}]},{"name":"Shanghai Shenkang Hospital Development Center Municipal Hospital Diagnosis and Treatment Technology Promotion and Optimization Management Project","award":["SHDC22024202"],"award-info":[{"award-number":["SHDC22024202"]}]},{"name":"Post-Market Clinical Research Program for Innovative Drugs","award":["WKZX2023CX210001"],"award-info":[{"award-number":["WKZX2023CX210001"]}]},{"DOI":"10.13039\/501100013098","name":"Scientific and Innovative Action Plan of Shanghai","doi-asserted-by":"publisher","award":["23S21900900"],"award-info":[{"award-number":["23S21900900"]}],"id":[{"id":"10.13039\/501100013098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2024-18-2"],"award-info":[{"award-number":["320.6750.2024-18-2"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Medical Innovation & Development Foundation","award":["SMIDF-142-1"],"award-info":[{"award-number":["SMIDF-142-1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00210-026-05178-z","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T03:54:24Z","timestamp":1773028464000},"page":"12305-12316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sex and age disparities in goserelin safety: a global pharmacovigilance study"],"prefix":"10.1007","volume":"399","author":[{"given":"Zizhen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuowen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guorong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuefen","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"issue":"6","key":"5178_CR1","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.psym.2013.12.008","volume":"55","author":"S Ahmadi-Davis","year":"2014","unstructured":"Ahmadi-Davis S, Velasco R, Stewart JT (2014) Goserelin-induced depression in a man with prostate cancer. Psychosomatics 55(6):720\u2013722. https:\/\/doi.org\/10.1016\/j.psym.2013.12.008","journal-title":"Psychosomatics"},{"issue":"1","key":"5178_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1464-410x.2004.04552.x","volume":"93","author":"H Akaza","year":"2004","unstructured":"Akaza H (2004) Adjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer. BJU Int 93(1):42\u201346. https:\/\/doi.org\/10.1111\/j.1464-410x.2004.04552.x","journal-title":"BJU Int"},{"key":"5178_CR3","unstructured":"AstraZeneca (1989) ZOLADEX\u00ae (goserelin acetate implant) Prescribing Information: AstraZeneca [Available from:  https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=020515. Accessed\u00a0 15 Oct 2025"},{"issue":"11","key":"5178_CR4","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1111\/j.1464-410X.2012.11107.x","volume":"110","author":"K Axcrona","year":"2012","unstructured":"Axcrona K, Aaltomaa S, da Silva CM et al (2012) Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. BJU Int 110(11):1721\u20131728. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11107.x","journal-title":"BJU Int"},{"key":"5178_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00187","volume":"11","author":"C Bizzarri","year":"2020","unstructured":"Bizzarri C, Cappa M (2020) Ontogeny of hypothalamus-pituitary gonadal axis and minipuberty: an ongoing debate? Front Endocrinol (Lausanne) 11:187. https:\/\/doi.org\/10.3389\/fendo.2020.00187","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"5178_CR6","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/s1470-2045(10)70223-0","volume":"11","author":"M Bolla","year":"2010","unstructured":"Bolla M, Van Tienhoven G, Warde P et al (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11(11):1066\u20131073. https:\/\/doi.org\/10.1016\/s1470-2045(10)70223-0","journal-title":"Lancet Oncol"},{"issue":"12","key":"5178_CR7","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/s1470-2045(19)30486-3","volume":"20","author":"C Carrie","year":"2019","unstructured":"Carrie C, Magn\u00e9 N, Burban-Provost P et al (2019) Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol 20(12):1740\u20131749. https:\/\/doi.org\/10.1016\/s1470-2045(19)30486-3","journal-title":"Lancet Oncol"},{"issue":"18","key":"5178_CR8","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.2165\/00003495-200565180-00011","volume":"65","author":"SM Cheer","year":"2005","unstructured":"Cheer SM, Plosker GL, Simpson D et al (2005) Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women. Drugs 65(18):2639\u20132655. https:\/\/doi.org\/10.2165\/00003495-200565180-00011","journal-title":"Drugs"},{"issue":"12","key":"5178_CR9","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.20892\/j.issn.2095-3941.2023.0335","volume":"20","author":"N Chen","year":"2024","unstructured":"Chen N, Wang Z, Chen M et al (2024) Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer. Cancer Biol Med 20(12):1047\u20131059. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2023.0335","journal-title":"Cancer Biol Med"},{"issue":"2","key":"5178_CR10","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2165\/00003495-199141020-00008","volume":"41","author":"P Chrisp","year":"1991","unstructured":"Chrisp P, Goa KL (1991) Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions. Drugs 41(2):254\u2013288. https:\/\/doi.org\/10.2165\/00003495-199141020-00008","journal-title":"Drugs"},{"issue":"22","key":"5178_CR11","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1200\/jco.2015.65.8864","volume":"34","author":"I Demeestere","year":"2016","unstructured":"Demeestere I, Brice P, Peccatori FA et al (2016) No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. J Clin Oncol 34(22):2568\u20132574. https:\/\/doi.org\/10.1200\/jco.2015.65.8864","journal-title":"J Clin Oncol"},{"issue":"3","key":"5178_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000463982","volume":"18","author":"F Di Silverio","year":"1990","unstructured":"Di Silverio F, Serio M, D\u2019Eramo G et al (1990) Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study. Eur Urol 18(3):54\u201361. https:\/\/doi.org\/10.1159\/000463982","journal-title":"Eur Urol"},{"key":"5178_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1349636","volume":"15","author":"L Ding","year":"2024","unstructured":"Ding L, Chen C, Yang Y et al (2024) Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data. Front Immunol 15:1349636. https:\/\/doi.org\/10.3389\/fimmu.2024.1349636","journal-title":"Front Immunol"},{"issue":"11","key":"5178_CR14","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1001\/jamaoncol.2025.3700","volume":"11","author":"PA Fasching","year":"2025","unstructured":"Fasching PA, Stroyakovskiy D, Yardley DA et al (2025) Ribociclib plus endocrine therapy in hormone receptor-positive\/ERBB2-negative early breast cancer: 4-year outcomes from the NATALEE randomized clinical trial. JAMA Oncol 11(11):1364\u20131372. https:\/\/doi.org\/10.1001\/jamaoncol.2025.3700","journal-title":"JAMA Oncol"},{"issue":"10","key":"5178_CR15","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1097\/cm9.0000000000002638","volume":"136","author":"C Gu","year":"2023","unstructured":"Gu C, Wang Z, Lin T et al (2023) Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: a multicenter, randomized, open-label, phase III, non-inferiority trial. Chin Med J (Engl) 136(10):1207\u20131215. https:\/\/doi.org\/10.1097\/cm9.0000000000002638","journal-title":"Chin Med J (Engl)"},{"key":"5178_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22062898","author":"MT Haider","year":"2021","unstructured":"Haider MT, Ridlmaier N, Smit DJ et al (2021) Interleukins as mediators of the tumor cell-bone cell crosstalk during the initiation of breast cancer bone metastasis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22062898","journal-title":"Int J Mol Sci"},{"issue":"8","key":"5178_CR17","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/bjc.2017.280","volume":"117","author":"R Haque","year":"2017","unstructured":"Haque R, UlcickasYood M, Xu X et al (2017) Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. Br J Cancer 117(8):1233\u20131240. https:\/\/doi.org\/10.1038\/bjc.2017.280","journal-title":"Br J Cancer"},{"key":"5178_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-12-393","volume":"12","author":"H Jiang","year":"2014","unstructured":"Jiang H, Wang T, Jiang Z (2014) Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer. World J Surg Oncol 12:393. https:\/\/doi.org\/10.1186\/1477-7819-12-393","journal-title":"World J Surg Oncol"},{"issue":"35","key":"5178_CR19","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1200\/jco.21.02844","volume":"40","author":"A Johansson","year":"2022","unstructured":"Johansson A, Dar H, van \u2019t Veer LJ et al (2022) Twenty-year benefit from adjuvant goserelin and tamoxifen in premenopausal patients with breast cancer in a controlled randomized clinical trial. J Clin Oncol 40(35):4071\u20134082. https:\/\/doi.org\/10.1200\/jco.21.02844","journal-title":"J Clin Oncol"},{"issue":"16","key":"5178_CR20","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.2169\/internalmedicine.0474-22","volume":"62","author":"K Kanazawa","year":"2023","unstructured":"Kanazawa K, Tomizawa Y, Iseki T et al (2023) Two elderly men with myasthenia gravis during androgen deprivation therapy for prostate cancer. Intern Med 62(16):2413\u20132414. https:\/\/doi.org\/10.2169\/internalmedicine.0474-22","journal-title":"Intern Med"},{"issue":"5","key":"5178_CR21","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/S0015-0282(16)53051-9","volume":"52","author":"IS Kang","year":"1989","unstructured":"Kang IS, Kuehl TJ, Siler-Khodr TM (1989) Effect of treatment with gonadotropin-releasing hormone analogues on pregnancy outcome in the baboon. Fertil Steril 52(5):846\u2013853","journal-title":"Fertil Steril"},{"issue":"10","key":"5178_CR22","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1093\/annonc\/mdq735","volume":"22","author":"P Karlsson","year":"2011","unstructured":"Karlsson P, Sun Z, Braun D et al (2011) Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Ann Oncol 22(10):2216\u20132226. https:\/\/doi.org\/10.1093\/annonc\/mdq735","journal-title":"Ann Oncol"},{"issue":"4","key":"5178_CR23","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1176\/appi.psy.47.4.360-a","volume":"47","author":"I Kohen","year":"2006","unstructured":"Kohen I, Koppel J (2006) Goserelin-induced new-onset depressive disorder. Psychosomatics 47(4):360\u2013361. https:\/\/doi.org\/10.1176\/appi.psy.47.4.360-a","journal-title":"Psychosomatics"},{"issue":"12","key":"5178_CR24","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1592\/phco.26.12.1811","volume":"26","author":"C Lam","year":"2006","unstructured":"Lam C, Tjon J, Hamilton J et al (2006) Recurrent anaphylaxis associated with gonadotropin-releasing hormone analogs: case report and review of the literature. Pharmacotherapy 26(12):1811\u20131815. https:\/\/doi.org\/10.1592\/phco.26.12.1811","journal-title":"Pharmacotherapy"},{"issue":"8","key":"5178_CR25","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/annonc\/mdx184","volume":"28","author":"RCF Leonard","year":"2017","unstructured":"Leonard RCF, Adamson DJA, Bertelli G et al (2017) GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol 28(8):1811\u20131816. https:\/\/doi.org\/10.1093\/annonc\/mdx184","journal-title":"Ann Oncol"},{"issue":"4","key":"5178_CR26","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/npp.2015.236","volume":"41","author":"J Macoveanu","year":"2016","unstructured":"Macoveanu J, Henningsson S, Pinborg A et al (2016) Sex-steroid hormone manipulation reduces brain response to reward. Neuropsychopharmacology 41(4):1057\u20131065. https:\/\/doi.org\/10.1038\/npp.2015.236","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"5178_CR27","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1111\/1756-185x.14692","volume":"26","author":"F Meng","year":"2023","unstructured":"Meng F, Su R, Ling L et al (2023) Erythema nodosum caused by goserelin acetate sustained-release: case report and literature review. Int J Rheum Dis 26(10):2055\u20132059. https:\/\/doi.org\/10.1111\/1756-185x.14692","journal-title":"Int J Rheum Dis"},{"issue":"10","key":"5178_CR28","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1056\/NEJMoa1413204","volume":"372","author":"HC Moore","year":"2015","unstructured":"Moore HC, Unger JM, Phillips KA et al (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372(10):923\u2013932. https:\/\/doi.org\/10.1056\/NEJMoa1413204","journal-title":"N Engl J Med"},{"issue":"3","key":"5178_CR29","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1067\/mob.2002.120485","volume":"186","author":"M Nowicki","year":"2002","unstructured":"Nowicki M, Adamkiewicz G, Bryc W et al (2002) The influence of luteinizing hormone-releasing hormone analog on serum leptin and body composition in women with solitary uterine myoma. Am J Obstet Gynecol 186(3):340\u2013344. https:\/\/doi.org\/10.1067\/mob.2002.120485","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"5178_CR30","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.3390\/curroncol30050364","volume":"30","author":"CM Oprean","year":"2023","unstructured":"Oprean CM, Ciocoiu AD, Segarceanu NA et al (2023) Pregnancy in a young patient with metastatic HER2-positive breast cancer-between fear of recurrence and desire to procreate. Curr Oncol 30(5):4833\u20134843. https:\/\/doi.org\/10.3390\/curroncol30050364","journal-title":"Curr Oncol"},{"issue":"4","key":"5178_CR31","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/00000441-199610000-00007","volume":"312","author":"SG Raj","year":"1996","unstructured":"Raj SG, Karadsheh AJ, Guillot RJ et al (1996) Case report: systemic hypersensitivity reaction to goserelin acetate. Am J Med Sci 312(4):187\u2013190. https:\/\/doi.org\/10.1097\/00000441-199610000-00007","journal-title":"Am J Med Sci"},{"issue":"2","key":"5178_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1517\/14656566.8.2.257","volume":"8","author":"M Roach 3rd","year":"2007","unstructured":"Roach M 3rd, Izaguirre A (2007) Goserelin acetate in combination with radiotherapy for prostate cancer. Expert Opin Pharmacother 8(2):257\u2013264. https:\/\/doi.org\/10.1517\/14656566.8.2.257","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"5178_CR33","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/s0959-8049(02)00810-9","volume":"39","author":"JF Robertson","year":"2003","unstructured":"Robertson JF, Blamey RW (2003) The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women. Eur J Cancer 39(7):861\u2013869. https:\/\/doi.org\/10.1016\/s0959-8049(02)00810-9","journal-title":"Eur J Cancer"},{"issue":"4","key":"5178_CR34","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1586\/14737140.5.4.591","volume":"5","author":"A Rody","year":"2005","unstructured":"Rody A, Loibl S, von Minckwitz G et al (2005) Use of goserelin in the treatment of breast cancer. Expert Rev Anticancer Ther 5(4):591\u2013604. https:\/\/doi.org\/10.1586\/14737140.5.4.591","journal-title":"Expert Rev Anticancer Ther"},{"key":"5178_CR35","doi-asserted-by":"publisher","first-page":"102684","DOI":"10.1016\/j.eclinm.2024.102684","volume":"73","author":"J Shen","year":"2024","unstructured":"Shen J, Hu R, Lin A et al (2024) Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase. EClinicalMedicine 73:102684. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102684","journal-title":"EClinicalMedicine"},{"issue":"3","key":"5178_CR36","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3349\/ymj.2007.48.3.421","volume":"48","author":"M Shiota","year":"2007","unstructured":"Shiota M, Tokuda N, Kanou T et al (2007) Incidence rate of injection-site granulomas resulting from the administration of luteinizing hormone-releasing hormone analogues for the treatment of prostatic cancer. Yonsei Med J 48(3):421\u2013424. https:\/\/doi.org\/10.3349\/ymj.2007.48.3.421","journal-title":"Yonsei Med J"},{"issue":"3","key":"5178_CR37","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/jco.1998.16.3.994","volume":"16","author":"CW Taylor","year":"1998","unstructured":"Taylor CW, Green S, Dalton WS et al (1998) Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 16(3):994\u2013999. https:\/\/doi.org\/10.1200\/jco.1998.16.3.994","journal-title":"J Clin Oncol"},{"issue":"1","key":"5178_CR38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1200\/JCO.18.00420","volume":"37","author":"V Turan","year":"2018","unstructured":"Turan V, Bedoschi G, Rodriguez-Wallberg K et al (2018) Utility of Gonadotropin-Releasing Hormone Agonists for Fertility Preservation: Lack of Biologic Basis and the Need to Prioritize Proven Methods. J Clin Oncol 37(1):84\u201386. https:\/\/doi.org\/10.1200\/JCO.18.00420","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"5178_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1289\/ehp.93101s291","volume":"101","author":"A Vermeulen","year":"1993","unstructured":"Vermeulen A (1993) Environment, human reproduction, menopause, and andropause. Environ Health Perspect 101(Suppl 2):91\u2013100. https:\/\/doi.org\/10.1289\/ehp.93101s291","journal-title":"Environ Health Perspect"},{"issue":"4","key":"5178_CR40","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/(SICI)1520-6394(1998)7:4<171::AID-DA5>3.0.CO;2-D","volume":"7","author":"JK Warnock","year":"1998","unstructured":"Warnock JK, Bundren JC, Morris DW (1998) Depressive symptoms associated with gonadotropin-releasing hormone agonists. Depress Anxiety 7(4):171\u2013177. https:\/\/doi.org\/10.1002\/(SICI)1520-6394(1998)7:4%3c171::AID-DA5%3e3.0.CO;2-D","journal-title":"Depress Anxiety"},{"issue":"1","key":"5178_CR41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jbo.2016.02.003","volume":"5","author":"C Wilson","year":"2016","unstructured":"Wilson C, Gossiel F, Leonard R et al (2016) Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover. J Bone Oncol 5(1):43\u201349. https:\/\/doi.org\/10.1016\/j.jbo.2016.02.003","journal-title":"J Bone Oncol"},{"issue":"1","key":"5178_CR42","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/annonc\/mds250","volume":"24","author":"M Wong","year":"2013","unstructured":"Wong M, O\u2019Neill S, Walsh G et al (2013) Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes. Ann Oncol 24(1):133\u2013138. https:\/\/doi.org\/10.1093\/annonc\/mds250","journal-title":"Ann Oncol"},{"issue":"10","key":"5178_CR43","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1089\/cbr.2012.1436","volume":"28","author":"S Wu","year":"2013","unstructured":"Wu S, Li Q, Zhu Y et al (2013) Role of goserelin in combination with endocrine therapy for the treatment of advanced breast cancer in premenopausal women positive for hormone receptor: a retrospective matched case-control study. Cancer Biother Radiopharm 28(10):697\u2013702. https:\/\/doi.org\/10.1089\/cbr.2012.1436","journal-title":"Cancer Biother Radiopharm"},{"issue":"3","key":"5178_CR44","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/bju.12905","volume":"116","author":"DR Ziehr","year":"2015","unstructured":"Ziehr DR, Chen MH, Zhang D et al (2015) Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int 116(3):358\u2013365. https:\/\/doi.org\/10.1111\/bju.12905","journal-title":"BJU Int"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05178-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05178-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05178-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:18:18Z","timestamp":1781511498000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05178-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5178"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05178-z","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical ethics and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}